1
|
Munir M, Setiawan H, Awaludin R, Kett VL. Aerosolised micro and nanoparticle: formulation and delivery method for lung imaging. Clin Transl Imaging 2023; 11:33-50. [PMID: 36196096 PMCID: PMC9521863 DOI: 10.1007/s40336-022-00527-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Accepted: 09/26/2022] [Indexed: 02/07/2023]
Abstract
Purpose The application of contrast and tracing agents is essential for lung imaging, as indicated by the wide use in recent decades and the discovery of various new contrast and tracing agents. Different aerosol production and pulmonary administration methods have been developed to improve lung imaging quality. This review details and discusses the ideal characteristics of aerosol administered via pulmonary delivery for lung imaging and the methods for the production and pulmonary administration of dry or liquid aerosol. Methods We explored several databases, including PubMed, Scopus, and Google Scholar, while preparing this review to discover and obtain the abstracts, reports, review articles, and research papers related to aerosol delivery for lung imaging and the formulation and pulmonary delivery method of dry and liquid aerosol. The search terms used were "dry aerosol delivery", "liquid aerosol delivery", "MRI for lung imaging", "CT scan for lung imaging", "SPECT for lung imaging", "PET for lung imaging", "magnetic particle imaging", "dry powder inhalation", "nebuliser", and "pressurised metered-dose inhaler". Results Through the literature review, we found that the critical considerations in aerosol delivery for lung imaging are appropriate lung deposition of inhaled aerosol and avoiding toxicity. The important tracing agent was also found to be Technetium-99m (99mTc), Gallium-68 (68Ga) and superparamagnetic iron oxide nanoparticle (SPION), while the essential contrast agents are gold, iodine, silver gadolinium, iron and manganese-based particles. The pulmonary delivery of such tracing and contrast agents can be performed using dry formulation (graphite ablation, spark ignition and spray dried powder) and liquid aerosol (nebulisation, pressurised metered-dose inhalation and air spray). Conclusion A dual-imaging modality with the combination of different tracing or contrast agents is a future development of aerosolised micro and nanoparticles for lung imaging to improve diagnosis success. Graphical abstract
Collapse
Affiliation(s)
- Miftakul Munir
- Research Center for Radioisotope Radiopharmaceutical and Biodosimetry Technology, National Research and Innovation Agency, South Tangerang, 15345 Indonesia
| | - Herlan Setiawan
- Research Center for Radioisotope Radiopharmaceutical and Biodosimetry Technology, National Research and Innovation Agency, South Tangerang, 15345 Indonesia
| | - Rohadi Awaludin
- Research Center for Radioisotope Radiopharmaceutical and Biodosimetry Technology, National Research and Innovation Agency, South Tangerang, 15345 Indonesia
| | - Vicky L. Kett
- School of Pharmacy, Queen’s University Belfast, 97 Lisburn Road, Belfast, BT9 7BL UK
| |
Collapse
|
2
|
Forest V, Pourchez J. Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient? Adv Drug Deliv Rev 2022; 183:114173. [PMID: 35217112 DOI: 10.1016/j.addr.2022.114173] [Citation(s) in RCA: 42] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Revised: 01/12/2022] [Accepted: 02/17/2022] [Indexed: 12/25/2022]
Abstract
Respiratory diseases gather a wide range of disorders which are generally difficult to treat, partly due to a poor delivery of drugs to the lung with adequate dose and minimum side effects. With the recent developments of nanotechnology, nano-delivery systems have raised interest. In this review, we detail the main types of nanocarriers that have been developed presenting their respective advantages and limitations. We also discuss the route of administration (systemic versus by inhalation), also considering technical aspects (different types of aerosol devices) with concrete examples of applications. Finally, we propose some perspectives of development in the field such as the nano-in-micro approaches, the emergence of drug vaping to generate airborne carriers in the submicron size range, the development of innovative respiratory models to assess regional aerosol deposition of nanoparticles or the application of nano-delivery to the lung in the treatment of other diseases.
Collapse
|
3
|
Montigaud Y, Pourchez J, Leclerc L, Tillement O, Clotagatide A, Bal C, Pinaud N, Ichinose N, Zhang B, Perinel S, Lux F, Crémillieux Y, Prevot N. Nebulised Gadolinium-Based Nanoparticles for a Multimodal Approach: Quantitative and Qualitative Lung Distribution Using Magnetic Resonance and Scintigraphy Imaging in Isolated Ventilated Porcine Lungs. Int J Nanomedicine 2020; 15:7251-7262. [PMID: 33061379 PMCID: PMC7533906 DOI: 10.2147/ijn.s260640] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Accepted: 08/18/2020] [Indexed: 12/11/2022] Open
Abstract
Purpose This study aims at determining lung distribution of gadolinium-based polysiloxane nanoparticles, AGuIX® (small rigid platform - SRP), as a potential theranostic approach by the pulmonary route. Methods First, the aerodynamic size distribution and the aerosol output rate were thoroughly characterized. Then, a multimodal approach using magnetic resonance (MR) and gamma-camera (GC) imaging allows to assess the deposition of the aerosolised nanoparticles in the respiratory tract using isolated ventilated porcine lungs. Results The SRP has proven to be radiolabelled by radioisotope with a good yield. Crude SRP or radiolabelled ones showed the same aerodynamic size distribution and output as a conventional molecular tracer, as sodium fluoride. With MR and GC imaging approaches, the nebulised dose represented about 50% of the initial dose of nanoparticles placed in the nebuliser. Results expressed as proportions of the deposited aerosol showed approximately a regional aerosol deposition of 50% of the deposited dose in the lungs and 50% in the upper airways. Each technique assessed a homogeneous pattern of deposited nanoparticles in Lungs. MR observed a strong signal enhancement with the SRP, similar to the one obtained with a commonly used MRI contrast agent, gadoterate meglumine. Conclusion As a known theranostic approach by intravenous administration, SRP appeared to be easily aerosolised with a conventional nebuliser. The present work proves that pulmonary administration of SRP is feasible in a human-like model and allows multimodal imaging with MR and GC imaging. This work presents the proof of concept of SRP nebulisation and aims to generate preclinical data for the potential clinical transfer of SRP for pulmonary delivery.
Collapse
Affiliation(s)
- Yoann Montigaud
- Mines Saint-Etienne, Univ Lyon, Univ Jean Monnet, INSERM, U 1059 Sainbiose, Centre CIS, Saint-Etienne, France
| | - Jérémie Pourchez
- Mines Saint-Etienne, Univ Lyon, Univ Jean Monnet, INSERM, U 1059 Sainbiose, Centre CIS, Saint-Etienne, France
| | - Lara Leclerc
- Mines Saint-Etienne, Univ Lyon, Univ Jean Monnet, INSERM, U 1059 Sainbiose, Centre CIS, Saint-Etienne, France
| | | | - Anthony Clotagatide
- INSERM U 1059 Sainbiose, Université Jean Monnet, Saint-Etienne, France.,CHU Saint-Etienne, Saint-Etienne, France
| | | | | | | | - Bei Zhang
- Canon Medical Systems Europe, Zoetermeer, Netherlands
| | - Sophie Perinel
- INSERM U 1059 Sainbiose, Université Jean Monnet, Saint-Etienne, France.,CHU Saint-Etienne, Saint-Etienne, France
| | - François Lux
- Institut Lumière Matière, Université de Lyon, Villeurbanne, France.,Institut Universitaire de France (IUF), Paris, France
| | | | - Nathalie Prevot
- INSERM U 1059 Sainbiose, Université Jean Monnet, Saint-Etienne, France.,CHU Saint-Etienne, Saint-Etienne, France
| |
Collapse
|
4
|
Sancey L, Sabido O, He Z, Rossetti F, Guignandon A, Bin V, Coll JL, Cottier M, Lux F, Tillement O, Constant S, Mas C, Boudard D. Multiparametric investigation of non functionalized-AGuIX nanoparticles in 3D human airway epithelium models demonstrates preferential targeting of tumor cells. J Nanobiotechnology 2020; 18:129. [PMID: 32912214 PMCID: PMC7488087 DOI: 10.1186/s12951-020-00683-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Accepted: 08/26/2020] [Indexed: 01/06/2023] Open
Abstract
Liquid deposit mimicking surface aerosolization in the airway is a promising strategy for targeting bronchopulmonary tumors with reduced doses of nanoparticle (NPs). In mimicking and studying such delivery approaches, the use of human in vitro 3D culture models can bridge the gap between 2D cell culture and small animal investigations. Here, we exposed airway epithelia to liquid-apical gadolinium-based AGuIX® NPs in order to determine their safety profile. We used a multiparametric methodology to investigate the NP’s distribution over time in both healthy and tumor-bearing 3D models. AGuIX® NPs were able to target tumor cells in the absence of specific surface functionalization, without evidence of toxicity. Finally, we validated the therapeutic potential of this hybrid theranostic AGuIX® NPs upon radiation exposure in this model. In conclusion, 3D cell cultures can efficiently mimic the normal and tumor-bearing airway epitheliums, providing an ethical and accessible model for the investigation of nebulized NPs. ![]()
Collapse
Affiliation(s)
- Lucie Sancey
- Institute for Advanced Biosciences, INSERM U1209, CNRS, UMR 5309, Université Grenoble Alpes, 38000, Grenoble, France.
| | - Odile Sabido
- INSERM U1059, Laboratoire SAINBIOSE, équipe DVH/PIB, Faculté de Médecine, Université Jean Monnet, Saint-Etienne, France.,Université de Lyon, Saint-Etienne, France
| | - Zhiguo He
- Université de Lyon, Saint-Etienne, France.,, BiiGC EA2521, Saint-Etienne, France
| | - Fabien Rossetti
- Institut Lumière Matière, CNRS UMR5306, Université Lyon 1, 69100, Villeurbanne, France
| | - Alain Guignandon
- Université de Lyon, Saint-Etienne, France.,SAINBIOSE, Inserm U1059, LBTO Team, Saint-Etienne, France
| | - Valérie Bin
- INSERM U1059, Laboratoire SAINBIOSE, équipe DVH/PIB, Faculté de Médecine, Université Jean Monnet, Saint-Etienne, France.,Université de Lyon, Saint-Etienne, France
| | - Jean-Luc Coll
- Institute for Advanced Biosciences, INSERM U1209, CNRS, UMR 5309, Université Grenoble Alpes, 38000, Grenoble, France
| | - Michèle Cottier
- INSERM U1059, Laboratoire SAINBIOSE, équipe DVH/PIB, Faculté de Médecine, Université Jean Monnet, Saint-Etienne, France.,Université de Lyon, Saint-Etienne, France.,CHU Saint Etienne, Hôpital Nord, UF6725 Cytologie et Histologie Rénale, St-Etienne, France
| | - François Lux
- Institut Lumière Matière, CNRS UMR5306, Université Lyon 1, 69100, Villeurbanne, France.,NH Theraguix, 38240, Meylan, France.,Institut Universitaire de France (IUF), Paris, France
| | - Olivier Tillement
- Institut Lumière Matière, CNRS UMR5306, Université Lyon 1, 69100, Villeurbanne, France.,NH Theraguix, 38240, Meylan, France
| | - Samuel Constant
- Epithelix SARL, Geneva, Switzerland.,OncoTheis SARL, Geneva, Switzerland
| | | | - Delphine Boudard
- INSERM U1059, Laboratoire SAINBIOSE, équipe DVH/PIB, Faculté de Médecine, Université Jean Monnet, Saint-Etienne, France. .,Université de Lyon, Saint-Etienne, France. .,CHU Saint Etienne, Hôpital Nord, UF6725 Cytologie et Histologie Rénale, St-Etienne, France.
| |
Collapse
|